Overview A Phase I Study of LP-168 in Healthy Volunteers Status: Recruiting Trial end date: 2022-11-02 Target enrollment: Participant gender: Summary This is a Phase I study designed to assess the safety, tolerability and pharmacokinetics of LP-168 in healthy human volunteers. Phase: Phase 1 Details Lead Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.